OnKure Therapeutics (OKUR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $20.00 price target.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sam Slutsky’s rating is based on OnKure Therapeutics’ strategic decision to delay the nomination of their pan-mutant selective PI3Ka inhibitor development candidate to the second half of 2025. This delay is attributed to the company’s thorough analysis of multiple promising candidates, aiming to select a molecule with high selectivity over wild type, which is crucial for addressing investor concerns about the efficacy of current clinical ‘pan-mutant’ PI3Ka inhibitors.
Furthermore, OnKure’s management has expressed confidence in the preclinical results of their pan-mutant molecules, indicating a strong potential for success. The company’s focus on achieving approximately 10-fold selectivity against common PI3Kα mutations over wild type demonstrates their commitment to developing a highly effective treatment, which supports the Buy rating given by Sam Slutsky.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is neutral on the stock.